None listed
Conditions
Brief summary
Children are often diagnosed with type 1 diabetes (T1D) too late, with 1 in 3 admitted to ICU with life-threatening diabetic ketoacidosis (DKA). This start to disease is traumatic and has lifelong implications for cognitive impairment, long-term blood glucose levels, and the risk of serious complications. Early diagnosis and starting treatment are essential to prevent DKA, reduce trauma and improve long-term health. Up to 90% of those who will develop T1D have no family history of the condition. Therefore, the only way to identify most children early is through general population screening. Our overarching vision is that general population screening for T1D will be implemented in Australia to decrease the burden of DKA and its health consequences. Australia is ideally suited to screening programs, given our centralised healthcare system with screening federally mandated, funded and managed. Several screening models have been proposed in research trials internationally, however, the optimal model for the Australian setting is unclear. The National Type 1 Diabetes Screening Pilot: Feasibility and Acceptability Study will compare three different models to determine the most appropriate model for routine screening of the Australian paediatric general population. Model 1) Newborn Screening via genetic analysis of a dried bloodspot taken in hospital at the same time as the current newborn screening sample. Genetically ‘at-risk’ children will be offered follow-up autoantibody bloodspot testing from 12 months of age. Model 2) Infants aged 6-12 months will be screened via genetic analysis of a saliva sample. Genetically ‘at-risk’ children will be offered follow-up autoantibody bloodspot testing from 12 months of age. Model 3) Children aged 2, 6 or 10 years old will be screened for islet autoantibodies using a dried bloodspot sample. Children with two or more autoantibodies are considered to have early stage T1D. We are aiming to recruit 9,000 children, with 3,000 children in each group from across Australia. Each screening model will run in a unique geographical area with public awareness and engagement campaigns, and targeted mail-out invitations to participate. The three screening models will be compared to see which was the most feasible, acceptable, and cost-effective. Collectively, this is a pivotal first step in achieving our overarching vision for general population screening for T1D to be implemented into routine healthcare across Australia, with the principal aim of reducing the burden of DKA and its lifelong health consequences for children.
Interventions
BRIEF NAME & WHY: The Type 1 Diabetes National Screening Pilot: Feasibility and Acceptability Study is a cluster-controlled implementation study comparing the feasibility, acceptability, and costs of three different screening models to identify the most appropriate strategy for type 1 diabetes screening in the paediatric general population in Australia. WHAT (MATERIALS & PROCEDURES): MATERIALS: Parents/guardians of all participating children will be provided with a hard-copy/electronic Participant Information Statement. Cohort 2 (infants aged 6–12 months) will receive a saliva swab self-sampling kit and instructions, and Cohort 3 (children aged 2, 6 or 10 years) will receive a capillary blood (finger prick) self-sampling kit and instructions. These resources will also be available to participating Primary Care Providers within the catchment areas should the parent/guardian require assistance from them in obtaining a sample from their child. In-school screening by a Registered Nurse will be offered to children in Cohort 3 (Kindergarten or Year 4) attending a participating school. Parent/guardians will also be provided with any relevant information relating to their child’s screening result e.g. explanation of the result, and/or recommendations for follow-up or specialist referral. PROCEDURES Cohort 1: Genetic screening (polygenic risk score) using newborn dried bloodspots (heel prick) with autoantibody follow-up of at-risk children at 12 months of age. Cohort 2: Genetic screening (polygenic risk score) using saliva at 6-12 months of age with autoantibody follow-up of at-risk children at 12 months of age. Cohort 3: Autoantibody screening using a capillary dried bloodspot (finger prick) in children aged 2, 6 or 10 years old OR in Kindergarten or Year 4. WHO DELIVERED/PROVIDED THE INTERVENTION & WHERE: Cohort 1 (newborns): The ‘intervention’ (i.e. dried bloodspot sampling for genetic analysis) will be performed by a research midwife, postnatal midwife, or hospital blood collector with pre-existing training in newborn heel prick blood spot collection. Cohort 2 (6-12 month old infants): The ‘intervention’ (i.e. saliva swab sampling for genetic analysis) can be performed in two ways according to participant preference. The saliva testing kits will be posted to registered families who can choose: 1) ‘self-sampling’ at home (i.e. the parent/guardian collects the sample from the infant); or 2) the parent/guardian can take the test kit to their Primary Care Provider who can perform the sample collection. Alternatively, selected Primary Care Providers will have test kits in their clinic, and they can screen and consent the participant and perform the swab during a routine consultation. Participating Primary Care Providers will have pre-existing training in saliva swab sample collection, and will receive protocol-specific training for sample collection. Cohort 3 (2, 6 and 10yr old children): The ‘intervention’ (i.e. dried capillary bloodspot sampling for autoantibody testing) can be performed in two ways according to participant preference. The finger prick blood test kits will be posted to registered families who can choose: 1) ‘self-sampling’ at home (i.e. the parent/guardian collects the sample from the infant); or 2) the parent/guardian can take the test kit to their Primary Care Provider who can perform the sample collection. Alternatively, selected Primary Care Providers will have test kits in their clinic, and they can screen and consent the participant and perform the blood spot collection during a routine consultation. Participating Primary Care Providers will have pre-existing training in finger prick blood spot sample collection, and will receive protocol-specific training for sample collection. Cohort 3 (children in Kindergarten or Year 4): The ‘intervention’ (i.e. dried capillary bloodspot sampling for autoantibody testing) will be performed in-school by a visiting registered nurse with pre-existing training in finger prick blood spot sample collection.
Sponsors
Study design
Eligibility
Inclusion criteria
Cohort 1: Newborns delivered in a recruiting hospital. Cohort 2: Infants aged 6 to 12 months AND residing in or attending a GP Practice/participating pharmacy in a relevant cohort catchment area. Cohort 3: Children aged 2 years old OR 6 years old OR 10 years old AND residing in or attending a GP Practice/participating pharmacy in a relevant cohort catchment area, OR attending Kindergarten or Year 4 at a participating primary school.
Exclusion criteria
Cohort 1: None Cohort 2: Pre-existing type 1 diabetes. Cohort 3: Pre-existing type 1 diabetes.